The American Journal of Managed Care

What Would Make Therapy Last? How About 2 Targets Each on B Cells and T Cells?

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

Biomunex Pharmaceuticals will showcase its MAIT Engager Platform during the 11th Annual Oncology Innovation Forum in San Francisco

Biomunex's CSO, Dr. Simon Plyte, is invited to present an oral communication during the 11th Annual Oncology Innovation Forum on the 10th of January 2026 in San Francisco (USA). -- The oral ...
European Medical Journal

In Vivo CAR T Shows Promise

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
BioWorld

Aptevo adds Nectin-4 x CD3 bispecific T-cell engager to pipeline

Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.
ascopubs.org

Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.

Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts. This is an ASCO Meeting Abstract from ...
The American Journal of Managed Care

In Vivo CAR T Takes Center Stage, With Results Shared for 4 MRD-Negative Patients

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...